- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02935244
Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections (ASPIRE-SSI)
연구 개요
상세 설명
The primary objective of ASPIRE-SSI is to determine the incidence of S. aureus infections, particularly S. aureus SSIs, in various adult surgical patient populations, and to identify the patient-related, pathogen-related, and contextual risk factors for the development of S. aureus SSI. Using this information, a SSI prediction tool will be derived for future clinical trials and public health interventions aimed at SSI prevention. Furthermore, immunologic features protective against S. aureus SSI will also be assessed.
The knowledge obtained by this study will enable identification of the surgical patients most at risk of developing S. aureus infections, particularly S. aureus SSI, and who would probably benefit most from new interventions given prophylactically and specifically to prevent S. aureus infections.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Assen, 네덜란드
- Wilhemina Ziekenhuis Assen
-
Breda, 네덜란드
- Amphia Hospital
-
Utrecht, 네덜란드
- UMC Utrecht
-
-
-
-
-
Bukarest, 루마니아
- Carol Davila University of Medicine and Pharmacy Bucharest
-
Bukarest, 루마니아
- Elias University Emergency Hospital
-
Bukarest, 루마니아
- Prof. C.C. Iliescu Cardiovascular Diseases Institute
-
Timişoara, 루마니아
- Clinic County Hospital Timisoara
-
-
-
-
-
Gent, 벨기에
- Algemeen Ziekenhuis Sint-Lucas & Volkskliniek Gent
-
Lier, 벨기에
- H. Hartziekenhuis
-
-
-
-
-
Belgrad, 세르비아
- Clinical Centre of Serbia
-
Belgrad, 세르비아
- Institute for Orthopedic Surgery Banjica
-
Kragujevac, 세르비아
- Clinical Centre of Kragujevac
-
-
-
-
-
Barcelona, 스페인
- Hospital Universitari de Bellvitge
-
Cadiz, 스페인
- Hospital Universitari del Mar
-
Córdoba, 스페인
- HU Reina Sophia
-
Oviedo, 스페인
- Hospital Universitario Central de Asturias
-
Sevilla, 스페인
- Hospital Universitario Virgen Macarena
-
-
-
-
-
Tallin, 에스토니아
- North Estonia Medical Centre
-
Tartu, 에스토니아
- Tartu University Clinic
-
-
-
-
-
Birmingham, 영국
- Queen Elizabeth Hospital
-
Brighton, 영국
- Brighton & Sussex University Hospital NHS Trust
-
Derby, 영국
- Derby Teaching Hospitals NHS Foundation Trust
-
Manchester, 영국
- The Pennine Acute Hospitals NHS Trust Manchester
-
Middlesbrough, 영국
- South Tees Hospitals NHS Foundation Trust
-
York, 영국
- York Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Ancona, 이탈리아
- Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona
-
Brescia, 이탈리아
- Brescia Hospital
-
Rimini, 이탈리아
- Ospedale Infermi di Rimini
-
-
-
-
-
Brno Střed, 체코
- St. Anne's University Hospital Brno
-
Nový Hradec Králové, 체코
- University hospital Hradec Králové
-
Ostrava, 체코
- University Hospital Ostrava
-
Praha, 체코
- University Hospital Motol
-
-
-
-
-
Limoges, 프랑스
- Centre Hospitalier Universitaire de Limoges
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients undergoing 1 of the protocol-defined surgical procedures are eligible for inclusion in the study. However, enrolment in the study cohort population will be based on preoperative S. aureus colonization. In total, approximately 3300 S. aureus colonized subjects and 1700 non-colonized subjects will be enrolled in the study cohort population.
Protocol-defined surgical procedures: Coronary artery bypass grafting; ICD implantation; knee and hip prosthesis surgery; laminectomy and spinal fusion surgery; emergency surgery; central artery reconstructive and peripheral artery bypass surgery; mastectomy; and craniotomy.
설명
Inclusion Criteria:
- The subject is 18 years of age or older.
- The subject is undergoing 1 of the protocol-defined surgical procedures. The surgical procedure is planned or unplanned.
- The subject has been screened for S. aureus colonization from three body regions: nose, throat, and perineum within 30 days prior to surgery, and based on the preoperative S. aureus colonization status of the subject, the subject qualifies for enrolment in the study cohort.
- Written informed consent has been obtained prior to enrollment in the study cohort.
Exclusion criteria:
- Parallel participation in any experimental study of an anti-Staphylococcus preventive intervention.
- An active diagnosis of a SSI as the reason for surgery.
- Not able to comply with study procedures and follow-up based on Investigator judgment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Incidence of S. aureus SSI
기간: Up to 90 days following surgery.
|
Up to 90 days following surgery.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of serious S. aureus SSI (deep and organ/space S. aureus SSI)
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of S. aureus bloodstream infection
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of other post-surgical S. aureus infection
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of all-cause SSI, by etiologic agent
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of S. aureus SSI stratified by antibiotic susceptibility
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Prevalence of preoperative S. aureus colonization in nose, throat and perineal region.
기간: No more than 30 days prior to surgery
|
No more than 30 days prior to surgery
|
|
|
Incidence of S. aureus SSI stratified by location of preoperative S. aureus colonization
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Incidence of post-surgical all-cause mortality
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
|
Semi-quantification of the bacterial load of colonizing S. aureus
기간: At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
|
|
Characterization of S. aureus isolates involved in colonization
기간: At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
Clonal type, gene sequence, and expression of certain virulence factors of S. aureus isolates
|
At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
|
Serum antibody levels against S. aureus virulence factors.
기간: Within 30 days prior to surgery (for the preoperative sample) and 2-6 weeks following the SSI episode (for the post-SSI sample)
|
Within 30 days prior to surgery (for the preoperative sample) and 2-6 weeks following the SSI episode (for the post-SSI sample)
|
|
|
Characterization of S. aureus isolates involved in infections
기간: Up to 90 days following surgery
|
Clonal type, gene sequence, and expression of certain virulence factors of S. aureus isolates
|
Up to 90 days following surgery
|
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
Magnitude of healthcare utilization associated with S. aureus SSI in terms of: a. Duration of length of stay (LOS) b. Incidence of readmissions, including re-interventions due to S. aureus SSI c. Duration of LOS during readmissions
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by participating country
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by type of surgery
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by wound classification
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by urgency of surgery
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI, stratified by American Society of Anesthesiologists Physical Score classification
기간: Up to 90 days following surgery
|
Up to 90 days following surgery
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NL57595.041.16
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
황색포도상구균에 대한 임상 시험
-
Baycrest완전한
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin완전한
-
Pharma Holdings ASCTC Clinical Trial Consultants AB완전한Staphylococcus Aureus의 비강 탈식민화스웨덴
-
Pharma Holdings ASCTC Clinical Trial Consultants AB완전한
-
Miquel PujolHospital Universitari de Bellvitge완전한
-
Catholic University of the Sacred HeartUniversity Hospital, Geneva; Universiteit Antwerpen; Clinical Centre of Serbia; Canisius-Wilhelmina... 그리고 다른 협력자들알려지지 않은ESBL 박테리아로 인한 감염 | 세균 저항 | 여러 약물에 대한 감염 저항성 | Staph Aureus 메티실린 내성 콜로니화이탈리아, 루마니아, 세르비아
-
Fraser HealthOndine Biomedical Inc.; Royal Columbian Hospital Foundation완전한